A ‘truly translational mindset’ requires the correct tool for the correct job: Synlogic

By Maggie Lynch

- Last updated on GMT

(Image: Getty/shironosov)
(Image: Getty/shironosov)

Related tags Translational medicine translational sciences Clinical research Patient centricity Clinical data preclinical preclinical development

Translational research faces new challenges – and opportunities – with the rapid growth in precision medicine and new drug modalities, as the industry looks to quickly bring new treatments to patients.

Aoife Brennan, president and CEO of Synlogic, will be speaking next week on a panel discussing the evolving models for translational research collaboration, new approaches to which could help accelerate the drug development process.

Synlogic uses its proprietary discovery platform to develop synthetic biotic medicines for rare genetic diseases and is currently collaborating with pharmaceutical companies like AbbVie, using its platform to help develop treatments for other diseases.

We spoke with Brennan ahead of the conference to further discuss the opportunities and challenges to translational research – the bridge between basic science and patient care​.

Expanding on this definition, Brennan said, “While it can sometimes be described as a phase of development – i.e. from target identification to proof of concept – in my view, it is a critical mindset even out to post-marketing.”

Brennan further explained that translational science is collaborative by nature​. “With recent advances in new tools and modalities as well as changes to how we do development, it requires even more expert collaboration,” ​she said.

An example of this, Brennan explained that for some new modalities, manufacturing issues can have a significant impact on the translation speed from bench to bedside.

Additionally, patient advocacy organizations are getting involved at earlier stages of development. “So, the number of stakeholders in development is increasing all the time,”​ she added.

But advancements in tools, research, and even discovery platforms, require translation​ into what Brennan refers to as “true health gains.” ​She added that these gains require traversing ‘the valley of death', and to do so, there needs to be further investment in basic science as well as policy and regulations.

Beyond regulations and biologic discoveries, there is also an opportunity for artificial intelligence (AI) to support translational science. AI can be used to create research models​ that can allow further prediction of how a biologic advancement can relate to drug development and how that drug can worth within a patient.

Brennan told us that with AI, “Our exponential increase in computing power has had and will continue to have an impact on every phase of development but a truly translational mindset requires us to select the correct tool for the correct job, to understand the assumptions and to interpret the resulting data appropriately.”

BIO International takes place next week in Philadelphia, PA.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us